Angiomax Drug maker Medicines Co. have announced that they have filed lawsuits in the U.S. District Court for the District of Delaware against Teva Pharmaceutical Laboratories Inc. and Pliva Hrvatsk following their submissions to the U.S. Food and Drug Administration to approve a generic version of the company’s anti-clotting agent Angiomax.
The IP Factor
Opinionated Intellectual Property News Blog with an Israel Slant
Michael Factor
